Celltrion to Showcase Omlyclo's Strengths at WAC 2026

Synergies expected with leading products including Remsima and Herzuma

Celltrion said on October 13 that it will participate in the World Allergy Congress (WAC 2026), taking place in Kyoto, Japan, from October 15 to 18, to showcase the competitive strengths and clinical evidence for Omlyclo and expand its engagement with healthcare professionals.

At its corporate booth, Celltrion will focus on presenting clinical data and the competitive strengths of Omlyclo, an omalizumab biosimilar set to launch in Japan.

In March, Omlyclo received marketing approval in Japan for bronchial asthma, chronic spontaneous urticaria (CSU), and seasonal allergic rhinitis, and is preparing for launch as a first-mover biosimilar following its inclusion on the drug price list.

On October 16, the second day of the congress, Celltrion will hold an academic seminar titled "Expanding Treatment Options Through Biosimilars: The Future of Asthma and Allergic Rhinitis Treatment." The seminar will share experiences using omalizumab in allergy care in Japan and the clinical value of biosimilars with more than 400 healthcare professionals.

Celltrion expects Omlyclo to generate synergies with leading products by leveraging its local subsidiary's sales and marketing capabilities once it launches, given the solid market shares in Japan held by Remsima (generic name: infliximab), an autoimmune disease treatment that entered the Japanese market earlier, as well as Yuflyma (generic name: adalimumab), Herzuma (generic name: trastuzumab), and Vegzelma (generic name: bevacizumab).

A Celltrion representative said, "Building on the strong trust and direct-sales infrastructure established in Japan by Remsima and Herzuma, we will do our utmost to help Omlyclo establish a leading position in Japan's allergy treatment market at an early stage."

This content was produced with the assistance of AI translation services.